AI Article Synopsis
- * Researchers analyzed data from 160 patients, focusing on mutations in KRAS, NRAS, BRAF, and PIK3CA, along with DNA mismatch repair status.
- * Results indicated that mutations in KRAS, BRAF, or PIK3CA were linked to worse outcomes, while DNA mismatch repair status did not influence prognosis; understanding these mutations can enhance the accuracy of survival predictions.
Article Abstract
Aim: To investigate the relationship between mutations of key genes in the EGFR signaling pathway and the prognosis of stage II colorectal cancer patients without chemotherapy.
Materials & Methods: The incidence of KRAS, NRAS, BRAF, PIK3CA mutations and deficient DNA mismatch repair were assessed in 160 stage II colorectal cancer patients who had been treated by radical operation without adjuvant chemotherapy.
Results: Mutations in KRAS, BRAF or PIK3CA were associated with poor prognosis, while the deficient DNA mismatch repair status was not associated with the prognosis. Combining these three markers, the sensitivity of the predicted value for poor progression-free survival and overall survival reached 0.645 (p = 0.002) and 0.709 (p = 0.001), respectively.
Conclusion: Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2017-0040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!